


SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 21, 2007

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
CA	5,510,396	4/23/1996	Prewett et al.
CA	6,340,477	1/22/2002	Anderson

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
CA	WO99/38543	8/5/1999	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

EXAMINER		DATE CONSIDERED	4/15/08
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 8, 2007

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
CA	2,967,802	1/10/1961	Towey et al.			
	3,608,071	9/21/1971	Relyveld et al.			
	3,925,545	12/9/1975	Relyveld			
	4,016,252	4/5/1977	Relyveld			
	4,108,690	8/22/1978	Heller			
	4,110,432	8/29/1978	Wilkinson et al.			
	4,157,378	6/5/1979	Tomlinson et al.			
	4,329,332	5/11/1982	Couvreux et al.			
	4,346,709	8/31/1982	Schmitt			
	4,347,234	8/31/1982	Wahlig et al.			
	4,353,888	10/12/1982	Sefton			
	4,429,691	2/7/1984	Niwa et al.			
	4,609,327	9/2/1986	Nishimori			
	4,612,053	9/16/1986	Brown et al.			
	4,620,327	11/4/1986	Caplan et al.			
	4,684,673	8/4/1987	Adachi			
	4,737,411	4/12/1988	Graves, Jr. et al.			
	4,842,603	6/27/1989	Draenert			
	4,849,193	7/18/1989	Palmer et al.			
	4,880,610	11/14/1989	Constantz			
CA	4,892,538	1/9/1990	Aebischer et al.			

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>4/15/02</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OK	Re. 33,161	2/6/1990	Brown et al.			
	4,917,702	4/17/1990	Scheicher et al.			
	Re. 33,221	5/22/1990	Brown et al.			
	4,938,938	7/3/1990	Ewers et al.			
OK	4,959,104	9/25/1990	Iino et al.			
	5,007,930	4/16/1991	Dorman et al.			
	5,034,059	7/23/1991	Constantz			
	5,043,059	7/23/1991	Constantz			
CA	5,037,639	8/6/1991	Tung			
	5,041,138	8/20/1991	Vacanti et al.			
	5,047,031	9/10/1991	Constantz			
	5,053,212	10/1/1991	Constantz et al.			
	5,085,861	2/4/1992	Gerhart et al.			
	5,129,905	7/14/1992	Constantz			
	5,149,368	9/22/1992	Liu et al.			
	5,152,836	10/6/1992	Hirano et al.			
	5,178,845	1/12/1993	Constantz et al.			
	5,197,985	3/30/1993	Caplan et al.			
	5,226,914	7/13/1993	Caplan et al.			
	5,258,044	11/2/1993	Lee			
	5,262,166	11/16/1993	Liu et al.			
	5,281,265	1/25/1994	Liu			
	5,286,763	2/15/1994	Gerhart et al.			
	5,306,305	4/26/1994	Lee			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 8, 2007

CA	5,336,264	8/9/1994	Constantz et al.			
	5,342,441	8/30/1994	Mandai et al.			
	5,352,715	10/4/1994	Wallace et al.			
	5,399,665	3/21/1995	Barrera et al.			
	5,443,832	8/22/1995	Amerongen et al.			
	5,462,751	10/31/1995	Kossovsky et al.			
	5,470,803	11/28/1995	Bonfield et al.			
	5,486,359	1/23/1996	Caplan et al.			
	5,496,399	3/5/1996	Ison et al.			
	5,508,342	4/16/1996	Antonucci et al.			
	5,514,378	5/7/1996	Mikos et al.			
	5,516,532	5/14/1996	Atala et al.			
	5,522,893	6/4/1996	Chow et al.			
	5,525,148	6/11/1996	Chow et al.			
	5,542,973	8/6/1996	Chow et al.			
	5,543,019	8/6/1996	Lee et al.			
	5,545,254	8/13/1996	Chow et al.			
	5,565,502	10/15/1996	Glimcher et al.			
	5,569,442	10/29/1996	Fulmer et al.			
	5,571,493	11/5/1996	Fulmer et al.			
	5,580,623	12/3/1996	Fulmer et al.			
	5,605,713	2/25/1997	Boltong			
	5,650,176	7/22/1997	Lee et al.			
CA	5,665,120	9/9/1997	Ohtsuka et al.			

EXAMINER

DATE CONSIDERED

4/15/08

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 8, 2007

CA	5,676,976	10/14/1997	Lee et al.			
	5,683,461	11/4/1997	Lee et al.			
	5,683,496	11/4/1997	Ison et al.			
	5,683,667	11/4/1997	Fulmer et al.			
	5,691,397	11/25/1997	Glimcher et al.			
	5,697,981	12/16/1997	Ison et al.			
	5,700,289	12/23/1997	Breitbart et al.			
	5,702,717	12/30/1997	Cha et al.			
	5,709,742	1/20/1998	Fulmer et al.			
	5,763,092	6/9/1998	Lee et al.			
	5,782,971	7/21/1998	Constantz et al.			
	5,783,217	7/21/1998	Lee et al.			
	5,795,330	8/18/1998	Tofighi et al.			
	5,820,632	10/13/1998	Constantz et al.			
	5,843,289	12/1/1998	Lee et al.			
	5,846,312	12/8/1998	Ison et al.			
	5,885,540	3/23/1999	Fulmer et al.			
	5,900,254	5/4/1999	Constantz			
	5,904,716	5/18/1999	Gendler			
	5,952,010	9/14/1999	Constantz			
	5,958,504	9/28/1999	Lee et al.			
	5,962,028	10/5/1999	Constantz			
	5,964,932	10/12/1999	Ison et al.			
CA	5,968,253	10/19/1999	Poser et al.			

EXAMINER <i>[Signature]</i>	DATE CONSIDERED 4/15/07
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007
(37 C.F.R. § 1.98(b))			

CA	5,980,482	11/9/1999	Tofighi et al.			
	6,002,065	12/14/1999	Constantz et al.			
	6,005,162	12/21/1999	Constantz			
	6,027,742	2/22/2000	Lee et al.			
	6,030,635	2/29/2000	Gertzman et al.			
	6,033,582	3/7/2000	Lee et al.			
	6,053,970	4/25/2000	Ison et al.			
	6,071,982	6/06/2000	Wise et al.			
	6,117,456	9/12/2000	Lee et al.			
	6,132,463	10/17/2000	Lee et al.			
	6,139,578	10/31/2000	Lee et al.			
	6,277,151	8/21/2001	Lee et al.			
	6,287,341	9/11/2001	Lee et al.			
	6,331,312	12/18/2001	Lee et al.			
	6,334,891	1/1/2002	Constantz et al.			
	6,443,988	9/03/2002	Felt et al.			
	6,461,631	10/08/2002	Dunn et al.			
	6,464,889	10/15/2002	Lee et al.			
	6,541,037	4/1/2003	Lee et al.			
	6,544,290	4/8/2003	Lee et al.			
	6,582,470	6/24/2003	Lee et al.			
	6,599,516	7/29/2003	Knaack			
	6,840,961	1/11/2005	Tofighi et al.			
CA	6,953,594	10/11/2005	Lee et al.			

EXAMINER

DATE CONSIDERED

4/15/08

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 8, 2007

<i>JA</i>	6,972,130	12/6/2005	Lee et al.			
	6,214,368	4/10/2001	Lee et al.			
	5,073,373	12/17/1991	O'Leary et al.			
	5,290,558	3/1/1994	O'Leary et al.			
	2002/0076429	6/20/2002	Wironen et al.			
	2002/0098222	7/25/2002	Wironen et al.			
	2002/0155137	10/24/2002	Lee et al.			
	2002/0155167	10/24/2002	Lee et al.			
	2002/0187104	12/12/2002	Li et al.			
	2003/0120351	6/26/2003	Tofighi et al.			
	2004/0002558	1/1/2004	McKay			
	2005/0106260	5/19/2005	Constantz et al.			
	2005/0147551	7/7/2005	Tofighi et al.			
	2005/0260278	11/24/2005	Constantz et al.			
	2005/0260279	11/24/2005	Constantz et al.			
	2006/0018974	1/26/2006	Constantz et al.			
<i>JA</i>	2004/0097612	5/20/2004	Rosenberg et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
<i>JA</i>	EP 0 268 463	5/25/1988	EPO			
	EP 0 347 028	12/20/1989	EPO			
<i>JA</i>	EP 0 419 275	3/27/1991	EPO			
	EP 0 664 133	7/26/1995	EPO			


EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>4/15/06</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007

CA	JP 63111875	5/17/1988	JPO (English Abstract)			
	JP 63170205	7/14/1988	JPO (English Abstract)			
	JP 2182261	7/16/1990	JPO (English Abstract)			
	JP 5305134	11/19/1993	JPO (English Abstract)			
	JP 6228011	8/16/1994	JPO (English Abstract)			
	JP 7277712	10/24/1995	JPO (English Abstract)			
	WO 92/00109	1/9/1992	WIPO			
	WO 92/02453	2/20/1992	WIPO			
	WO 94/02412	2/3/1994	WIPO			
	WO 94/04657	3/3/1994	WIPO			
	WO 94/08458	4/28/1994	WIPO			
	WO 94/20064	9/15/1994	WIPO			
	WO 94/25080	11/10/1994	WIPO			
	WO 95/08319	3/30/1995	WIPO			
	WO 96/03160	2/8/1996	WIPO			
	WO 96/36562	11/21/1996	WIPO			
	WO 97/17285	5/15/1997	WIPO			
	WO 98/16209	4/23/1998	WIPO			
CA	WO 01/08714	2/8/2001	WIPO			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)


CA	Aggerbeck and Heron, "Adjuvantcity of Aluminum Hydroxide and Calcium Phosphate in Diptheria-Tetanus Vaccines I," <i>Vaccine</i> 13:1360-1365 (1995).
	Alper et al. "Osteogenesis in Bone Defects in Rats: The Effects of Hydroxyapatite and Demineralized Bone Matrix," <i>Am. J. Med. Sci.</i> 298:371-376 (1989).
CA	Aoki, "Science and Medical Applications of Hydroxyapatite," <i>JAAS</i> 11-15 (1991).

EXAMINER 	DATE CONSIDERED <u>4/15/08</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	




SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007
(37 C.F.R. § 1.98(b))			

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

CA	Appel et al., "Recent Advances in Implants for Bone Growth Promotion," <i>Exp. Opin. Ther. Patents</i> 4:1461-1469 (1994).
	Atala et al., "Injectable Alginate Seeded with Chondrocytes as a Potential Treatment for Vesicoureteral Reflux," <i>J. Urol.</i> 150:745-747 (1993).
	Athanasou, "Cellular Biology of Bone-Resorbing Cells," <i>J. Bone Joint Surg. Am.</i> 78:1096-1112 (1996).
	Attawia et al., "Osteoblast-Like Cell Adherence and Migration Through 3-Dimensional Porous Polymer Matrices," <i>Biochem. Biophys. Res. Commun.</i> 213:639-644(1995).
	Barton et al., "Surface and Bulk Properties of Amorphous Calcium Phosphate," <i>Surface Chem. Colloids</i> 87: 379 No. 73954v (1977).
	Benghuzzi et al., "Alcap Ceramic Implantable Devices and the Effect of Surface Area on the Delivery of Various Steroid Hormones," 8th Southern Biomedical Engineering Conference, Richmond, VA, October 15-16, 1989; <i>Biomater. Artif. Cells Artif. Organs</i> , 17:463 (1989).
	Benghuzzi et al., "Long-Term Delivery of Danazol by Biodegradable Ceramic Devices," 8th Southern Biomedical Engineering Conference, Richmond, VA, October 15-16, 1989; <i>Biomater. Artif. Cells Artif. Organs</i> , 17:463 (1989).
	Benghuzzi et al., "Resorbable and Biodegradable Ceramics as Drug Delivery Systems," 8th Southern Biomedical Engineering Conference, Richmond, VA, October 15-16, 1989; <i>Biomater. Artif. Cells Artif. Organs</i> , 17:463 (1989).
	Benghuzzi et al., "Controlled Release of Hydrophilic Compounds by Resorbable and Biodegradable Ceramic Drug Delivery Devices," <i>Biomed. Sci. Instrum.</i> 28:179-182 (1992).
	Besic et al., "Electron Probe Microanalysis of Noncarious Enamel and Dentin and Calcified Tissues in Mottled Teeth," <i>J. Dent. Res.</i> 48:131-139 (1969).
	Bonfield, "Chapter 16- Design of Bioactive Ceramic-Polymer Composites," <i>An Introduction to Biometrics, IRC in Biomedical Materials</i> , Queen Mary and Westfield College, London, UK, 16:299-303.
	Boskey, "Matrix Proteins and Mineralization: An Overview," <i>Connect. Tissue Res.</i> 35:357-363 (1996).
	Brown, "Phase Relationships in the Ternary System CaO-P <sub>2</sub> O <sub>5</sub> -H <sub>2</sub> O at 25°C," <i>J. Am. Ceram. Soc.</i> 75:17-22 (1992).
	Cannon et al., "Continuous Delivery of Azidothymidine by Hydroxyapatite or Tricalcium Phosphate Ceramics," <i>Biomed. Sci. Instrum.</i> 31:159-164 (1995).
	Chung et al., "Biological Effects of Drug-Loaded Biodegradable Membranes for Guided Bone Regeneration," <i>J. Periodont. Res.</i> 32:172-175 (1997).
CA	Constantz et al., "Skeletal Repair by <i>in Situ</i> Formation of the Mineral Phase of Bone," <i>Science</i> 267:1796-1799 (1995).
EXAMINER 	DATE CONSIDERED 4/15/06
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

CA	Covey et al., "Clinical Induction of Bone Repair with Demineralized Bone Matrix or a Bone Morphogenetic Protein," <i>Orthop. Rev.</i> 18:857-863 (1989).
	Denissen et al., "Net-Shaped Hydroxyapatite Implants for Release of Agents Modulating Periodontal-Like Tissues," <i>J. Periodontal Res.</i> 32:40-46(1997).
	Driessens et al., "Calcium Phosphate Bone Cements," <i>Encyc. Hand. Biomat. Bioeng.</i> , pp. 855-877 (1995).
	Ducheyne et al., "Chapter 15: Bioceramic Composites," In <i>Advanced Series in Ceramics-Vol. 1: An Introduction to Bioceramics</i> , 281-297 (1993).
	Eanes et al., "Intermediate States in the Precipitation of Hydroxyapatite," <i>Nature</i> 208:365-367 (1965).
	Eanes et al. "Intermediate Phases in the Basic Solution Preparation of Alkaline Earth Phosphates," <i>Chemical Abstracts</i> 69:10348, no. 110373f (1968).
	Eanes, "Thermochemical Studies on Amorphous Calcium Phosphate," <i>Calcif. Tissue Res.</i> 5:133-145 (1970).
	Elgendy et al., "Osteoblast-Like Cell (MC3T3-E1) Proliferation on Bioerodible Polymers: An Approach Towards the Development of a Bone-BioErodible Polymer Composite Material," <i>Biomater.</i> 14:263-269 (1993).
	Fabbri et al., "Hydroxyapatite-Based Porous Aggregates: Physico-Chemical Nature, Structure, Texture and Architecture," <i>Biomater.</i> 16: 225-228 (1995).
	Fink and Simonsmeier, "Business Laws," <i>Rem. Pharm. Sci.</i> 17 <sup>th</sup> Ed. 1890-1891 (1985).
	Freed et al., "Cultivation of Cell-Polymer Cartilage Implants in Bioreactors," <i>J. Cellular Biochemistry</i> 51:257-264 (1993).
	Freed et al., "Biodegradable Polymer Scaffolds for Tissue Engineering," <i>Biotech.</i> 12:689-693 (1994).
	Gennaro, ed., "Clinical/ Medical Testing," <i>Rem. Pharm. Sci.</i> 17 <sup>th</sup> Ed. 39-40 (1985).
	Glimcher et al., "Recent Studies of Bone Mineral: Is the Amorphous Calcium Phosphate Theory Valid," <i>J. Crystal Growth</i> 53:100-119 (1981).
	Glimcher, "Recent Studies of the Mineral Phase in Bone and its Possible Linkage to the Organic Matrix by Protein-Bound Phosphate Bonds," <i>Philos. Trans. R. Soc. Lond. B.</i> 304:479-508 (1984).
	Glowacki et al., "Demineralized Bone Implants," <i>Clin. Plast. Surg.</i> 12:233-241 (1985).
	Goto et al., "Studies on the Toxicities of Aluminum Hydroxide and Calcium Phosphate as Immunological Adjuvants for Vaccines," <i>Vaccine</i> 11:914-918 (1993).
CA	Goto et al., "Local Tissue Irritating Effects and Adjuvant Activities of Calcium Phosphate and Aluminum Hydroxide with Different Physical Properties," <i>Vaccine</i> 15:1364-1371 (1997).


EXAMINER 	DATE CONSIDERED 4/15/08
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))


CA	Graves et al., "Resorbable Ceramic Implants," <i>J. Biomed. Mater. Res. Symposium</i> 2:91-115 (1971).
	Greenfield et al., "Formation Chemistry of Amorphous Calcium Phosphates Prepared from Carbonate Containing Solutions," <i>Calc. Tiss. Res.</i> 9:152-162 (1972).
	Gupta et al., "Adjuvants - A Balance Between Toxicity and Adjuvanticity," <i>Vaccine</i> 11:293-306 (1993).
	Gupta et al., "Comparison of Adjuvant Activities of Aluminum Phosphate, Calcium Phosphate and Stearyl Tyrosine for Tetanus Toxoid," <i>Biologicals</i> 22:53-63 (1994).
	Hirasawa et al., "Manufacture of High Purity Hydroxyapatite," <i>Chemical Abstracts</i> , 108:166-167, no. 78193h (1988).
	Holmes et al., "Surface Areas by Gas Adsorption on Amorphous Calcium Phosphate and Crystalline Hydroxyapatite," <i>Calc. Tiss. Res.</i> 7:163-174 (1971).
	Hubbell, "Biomaterials in Tissue Engineering," <i>Biotech.</i> 13:565-576 (1995).
	Ickovic et al., "Calcium-Phosphate-Adjuvanted Allergens: Total and Specific IgE Levels Before and After Immunotherapy with House Dust and <i>Dermatophagoides Pteronyssinus</i> Extracts," <i>Ann. Immunol.</i> 134D:385-398 (1983).
	Jnterna et al., "Hydroxyapatite Microcarriers for Biocontrolled Release of Protein Drugs," <i>Int'l. J. Pharm.</i> 112:215-224 (1994).
	Ikada et al., "Release of Antibiotic from Composites of Hydroxyapatite and Poly(lactic acid)," <i>J. Control. Release</i> 2:179-186 (1985).
	Ishaug et al., "Osteoblast Function on Synthetic Biodegradable Polymers," <i>J. Biomed. Mater. Res.</i> 28:1445-1453 (1994).
	Ishikawa et al., "Effects of Preparation Conditions in Aqueous Solution on Properties of Hydroxyapatites," <i>Chemical Abstracts</i> , 113: 6001, no. 218168 (1990).
	Itokazu et al., "Drug Delivery Systems Using Porous Hydroxyapatite Blocks," <i>J. Orthop. Surg.</i> 2:47-50 (1994).
	Kato et al., "Relationship Between Hemolytic Activity and Adsorption Capacity of Aluminum Hydroxide and Calcium Phosphate as Immunological Adjuvants for Biologicals," <i>Microbiol. Immunol.</i> 38:543-548 (1994).
	Knaack et al., "Novel Fully Resorbable Calcium Phosphate Bone Substitute," 1997 ASBMR Abstract, 12: s202, (1997).
	Knaack, "Endothermically Setting Calcium Phosphate Bone Substitute," Orthopaedic Congress, August 20-22, 1997, Boston, MA.
CA	Knaack et al., "A Fully Resorbable Calcium Phosphate Bone Substitute," Portland Bone Symposium, pp692-701, (1997).

EXAMINER 	DATE CONSIDERED <u>4/15/05</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007


(37 C.F.R. § 1.98(b))

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

A	Kossovsky et al., "Surface-Modified Nanocrystalline Ceramics for Drug Delivery Applications," <i>Biomaterials</i> 15:1201-1207 (1994).
	Kossovsky et al., "Preservation of Surface-Dependent Properties of Viral Antigens Following Immobilization on Particulate Ceramic Delivery Vehicles," <i>J. Biomed. Mat. Res.</i> 29:561-573 (1995).
	Kreuter et al., "Influence of the Particle Size on the Adjuvant Effect of Particulate Polymeric Adjuvants," <i>Vaccine</i> 4:125-129 (1986).
	Labarthe et al., "Sur la Structure et les Propriétés des Apatites Carbonatées de Type B Phospho-Calciques," <i>Ann. Chem.</i> 8:289-301 (1973).
	Mileti et al., "Development of a Hydroxyapatite Ceramic Matrix for the Continuous Delivery of Coumadin," <i>Biomed. Sci. Instrum.</i> 31:177-182 (1995).
	Moldovan et al., "A Ceramic System for Continuous Release of Acetylsalicylic Acid," <i>Biomed. Sci. Instrum.</i> 30:175-180 (1994).
	Moldovan et al., "Continuous Delivery of Analgesics by Ceramics," Fifth World Biomaterials Congress, Toronto, Canada, June 2, 1996. (Abstract only).
	Norian Corporation, Product Information Sheet, "The Material Science of Norian SRS™, Skeletal Repair System™," (1997).
	Nylon et al., "Molecular and Ultrastructural Studies of Non-Crystalline Calcium Phosphates," <i>Calcif. Tissue Res.</i> 9:95-108 (1972).
	Otsuka et al., "Drug Release Behavior from Self-Setting Calcium Phosphate Cement Containing Anti-Cancer Drug," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> 21:268-269 (1994).
	Otsuka et al., "A Novel Skeletal Drug Delivery System Using Self-Setting Calcium Phosphate Cement. 4: Effects of the Mixing Solution Volume on the Drug Release Rate of Heterogenous Aspirin-Loaded Cement," <i>J. Pharm. Sci.</i> 83:259-263 (1994).
	Otsuka et al., "A Novel Skeletal Drug Delivery System Using Self-Setting Calcium Phosphate Cement. 9: Effects of the Mixing Solution Volume on Anticancer Drug Release from Homogeneous Drug-Loaded Cement," <i>J. Pharm. Sci.</i> 84:733-736 (1995).
	Otsuka et al., "Effect of Particle Size of Metastable Calcium Phosphates on Mechanical Strength of a Novel Self-Setting Bioactive Calcium Phosphate Cement," <i>J. Biomed. Mater. Res.</i> 29:25-32 (1995).
	Pool, "Coral Chemistry Leads to Human Bone Repair," <i>Science</i> 267:1772 (1995).
	Posner et al., "Synthetic Amorphous Calcium Phosphate and its Relation to Bone Mineral Structure," <i>Bone Mineral Structure</i> , 8: 273-281 (1975).
A	Redondo et al., "Effect of particulate porous hydroxyapatite on osteoinduction of demineralized bone autografts in experimental reconstruction of the rat mandible," <i>Int. J. Oral. Maxillofac. Surg.</i> 24:445-448 (1995)
EXAMINER 	DATE CONSIDERED 4/15/08
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	04712/050002
	Serial No.	10/822,540
	Applicant	Rosenberg et al.
	Filing Date	April 12, 2004
	Group	1615
	IDS Filed	May 8, 2007

CA	Relyveld, "Current Developments in Production and Testing of Tetanus and Diphtheria Vaccines," <i>New Developments with Human and Veterinary Vaccines</i> , pp. 51-76 (1980).
	Relyveld et al., "Calcium Phosphate Adjuvanted Allergens," <i>Annals of Allergy</i> 54:521-529 (1985).
	Relyveld et al., "Preparation and Use of Calcium Phosphate Adsorbed Vaccines," <i>Develop. Biol. Standard</i> 65:131-136 (1986).
	Relyveld et al., "Humoral Response in Rabbits Immunized with Calcium Phosphate Adjuvanted HIV-1 gp160 Antigen," <i>Biomed. &amp; Pharmacother.</i> 48:79-83 (1994).
	Rey et al., "The Carbonate Environment in Bone Mineral: A Resolution-Enhanced Fourier Transform Infrared Spectroscopy Study," <i>Calcif. Tissue Int.</i> 45:157-164 (1989).
	Rey et al., "Structural Studies of the Mineral Phase of Calcifying Cartilage," <i>J. Bone Miner. Res.</i> 6:515-525 (1991).
	Rey et al., "Preparation of Microporous Ceramic at Low Temperature from Poorly Crystalline Apatite," <i>Symposium V: Hydroxyapatite and related compounds</i> (Abstract only) (1993).
	Rey et al., "Chemical Properties of Poorly Crystalline Apatites" <i>Phosphorus Res. Bull.</i> 6:67-70 (1996). (Abstract only)
	Shinto et al., "Calcium Hydroxyapatite Ceramic Used as a Delivery System for Antibiotics," <i>J. Bone Joint Surg. Br.</i> 74-B:600-604 (1992).
	Shors et al., "Chapter 10: Porous Hydroxyapatite," In <i>An Introduction to Bioceramics</i> , eds. Hersch et al., Work Sci. Publ. Co. Pte. Ltd.: 181-198 (1993).
	Termine et al., "Amorphous/Crystalline Interrelationships in Bone Mineral," <i>Calc. Tissue Res.</i> 1: 8-23 (1967).
	Thoma et al., "Biodegradable Gentamicin Depot-Implants Made of Beta-Tricalcium Phosphate Ceramics. 3: In Vivo Studies on Drug Release, Tissue Tolerance, and Biodegradation," <i>Pharmazie</i> 46:266-270 (1991) (Abstract only).
	Thoma et al., "Biodegradable Controlled Release Implants Based on $\beta$ -Tricalcium Phosphate Ceramic," <i>Eur. J. Pharm. Biopharm.</i> 38:107-112 (1992).
	Thomson et al., "Fabrication of Biodegradable Polymer Scaffolds to Engineer Trabecular Bone," <i>J. Biomater. Sci. Polym. Edn.</i> 7:23-30 (1995).
CA	Törmälä, "Biodegradable Self-Reinforced Composite Materials; Manufacturing Structure and Mechanical Properties," <i>Clin. Mater.</i> 10:29-34 (1992).

EXAMINER		DATE CONSIDERED	4/15/08
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04712/050002
		Serial No.	10/822,540
		Applicant	Rosenberg et al.
		Filing Date	April 12, 2004
		Group	1615
		IDS Filed	May 8, 2007

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

	Tung et al., "An Intermediate State in Hydrolysis of Amorphous Calcium Phosphate," <i>Calcif. Tissue Int.</i> 35:783-790 (1983).
	Tung, "In Vitro Drug Release of Antibiotic-Loaded Porous Hydroxyapatite Cement," <i>Artif. Cells Blood Substit. Immob. Biotech.</i> 23:81-88 (1995).
	Uchida et al., "Slow Release of Anticancer Drugs from Porous Calcium Hydroxyapatite Ceramic," <i>J. Orthop. Res.</i> 10:440-445 (1992).
	Vassilev, "Aluminium Phosphate But Not Calcium Phosphate Stimulates the Specific IgE Response in Guinea Pigs to Tetanus Toxoid," <i>Allergy</i> 33:155-159 (1978).
	Yamamura et al., "Antitumor Effects and Distrubutions of Adriamycin Incorporated Into Hydroxyapatite Implants in a Cancer Rat Model Bearing Swarm Rat Chondrosarcoma," <i>Japan. J. Pharm.</i> 66:433-438 (1994).
	Yamamura et al., "Anticancer Effects of Adriamycin-Loaded Hydroxyapatite Implants Determined in a Swarm Rat Chondrosarcoma Model," <i>Japan. J. Pharm.</i> 65:289-291 (1994).
	Yasue et al., "Effect of Adsorption of Succinic Acid on the Formation of Amorphous Calcium Phosphate," <i>J. Ceramic Soc. Japan (International Edition)</i> , 102: 1125-1130 (1994).

EXAMINER	DATE CONSIDERED <u>4/15/08</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	